ORCL is trading at $150.28 after a post-earnings week that illustrated a familiar pattern: strong results, punishing price action, and now an analyst community busy adjusting expectations downward without abandoning the bull case.
The analyst response to Thursday's Q1 FY2027 print tells a nuanced story. The broad direction on September 11 was target resets, not downgrades. Stifel cut its target from $220 to $200. BMO Capital trimmed from $220 to $195. RBC Capital was the starkest, dropping from $190 to $165 while sitting at Sector Perform — the clearest vote of caution in the batch. Offsetting that, UBS raised to $250 and Barclays lifted to $252, both maintaining Overweight. TD Cowen, DA Davidson, Guggenheim, and Cantor Fitzgerald all held their buy-side ratings unchanged. The consensus remains firmly at Buy across 27 firms, with the mean target near $239 — implying roughly 59% upside from current levels. That gap between where analysts think the stock belongs and where it is trading is the defining tension of the Oracle story right now. Note that Guggenheim's $400 target is a significant outlier and pulls the mean noticeably above where the cluster of targets sits.
The bull case rests on numbers that genuinely warrant excitement. Cloud revenue hit $8.9 billion in the latest quarter, up 41% year-over-year. AI infrastructure demand jumped 243%. Multi-cloud database services grew 531%. Remaining performance obligations rose 325%, and FY27 revenue guidance was raised to $90 billion. Oracle's own forward earnings expectations have roughly doubled over the past year — the EPS momentum factor scores rank in the 69th percentile at both 30- and 90-day horizons. Bears counter that competition in the database and middleware markets is structurally intensifying, that AI monetisation expectations are running ahead of what can be delivered near-term, and that high international exposure adds meaningful currency and regulatory risk. The company's short score has nudged down to 30.4 from 31.3 a week ago — a minor easing, but consistent with the picture of short sellers quietly exiting rather than pressing the trade.
That exit is confirmed in the positioning data. Short interest has fallen 11% on the week to 1.5% of free float — already low, now lower. Borrow availability is effectively unlimited; the lending pool is so deep that there is no mechanical pressure driving the stock lower from the short side. Cost to borrow spiked briefly to nearly 2.9% on September 7, but collapsed back to 0.34% by September 10. That spike looks like a transient settlement quirk around the earnings date rather than any genuine demand for borrows. The put/call ratio at 0.86 is almost exactly in line with its 20-day average of 0.85, sitting less than 0.2 standard deviations above the mean. Options traders are not hedging defensively — a meaningful shift from the elevated protection demand flagged in pre-earnings notes. Lending and options together confirm the same message: this is not a short-driven decline.
Ownership context adds one layer worth noting. Lawrence Ellison holds 40% of shares outstanding. The concentration means institutional float is relatively thin — passive holders like BlackRock (5%) and Vanguard (4.2%) dominate the free float alongside State Street. Capital Research added 7.3 million shares through August, the largest recent active move among institutions. The Vice Chairman Jeffrey Henley's June trades — option exercises followed by open-market sales under a pre-arranged 10b5-1 plan — are mechanical compensation activity rather than a conviction signal, and the plan structure means they tell us nothing about his view on the stock.
Among peers, CDNS fell 5.1% on the week and MSFT dropped 2.8% — both meaningfully less than Oracle's 5.4% decline. REKR shed 11.5%, the only peer that fared worse. The pattern suggests ORCL's relative underperformance is not purely a sector-rotation trade. Something specific to Oracle's valuation reset is driving it — the PE multiple has contracted to 15.2x on a trailing basis, with EV/EBITDA compressing to 8.7x, both down on the week and the month. The market is repricing the multiple even as the fundamental growth story holds up. What to watch next is whether the $150 level holds as institutional buyers step in to narrow that analyst-to-price gap, or whether the multiple compression has further to run before the stock finds equilibrium with its own backlog conversion story.
See the live data behind this article on ORTEX.
Open ORCL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
